Rajeev R Shah1*, Tracy William2, Apoorwa Gupta3
1Professor and Head, Microbiology Department, PMCH, Udaipur, India
2William Dental Clinic, Peris, France
3Apollo Hospital, Indore, India
*Corresponding Author: Rajeev R Shah, Professor and Head, Microbiology Department, PMCH, Udaipur, India.
Received: December 24, 2019; Published: February 01, 2020
The Human Immunodeficiency Virus (HIV) has changed from life threatening to chronic condition due to the almost universal use and accessibility of antiretroviral treatment (ART) among HIV patients. Antiretroviral (ARV) treatment works by suppressing the viral load and restoring the immune system. Once patients start Highly Active Antiretroviral Therapy (HAART), it is to be continued lifelong in spite of its many adverse side effects. Zidovudine (AZT) a nucleoside reverse transcriptase inhibitor is the first line antiretroviral regimen in India, and was the first break through in AIDS therapy in 1990. It is known to be associated with life threatening toxicity like anaemia.
Citation: Rajeev R Shah., et al. “Survey of HAART/ART in HIV/AIDS Patients". Acta Scientific Pharmaceutical Sciences 4.3 (2020): 01.
Copyright: © 2020 Rajeev R Shah., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
×
Copyright
+91 9182824667
Open Access by
Acta Scientific is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at https://actascientific.com
ff
